Q1 2024 EPS Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Raised by Analyst

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities research analysts at Leerink Partnrs increased their Q1 2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research report issued to clients and investors on Monday, April 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn ($0.61) per share for the quarter, up from their prior estimate of ($0.64). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.65 EPS.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The firm had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same quarter last year, the company posted ($0.76) EPS.

A number of other equities analysts have also recently issued reports on MRNS. Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday. StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $18.21.

Marinus Pharmaceuticals Stock Performance

MRNS stock opened at $1.44 on Thursday. The stock has a 50-day moving average price of $8.72 and a two-hundred day moving average price of $8.45. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $11.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently bought and sold shares of MRNS. Point72 Asset Management L.P. acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $13,990,000. BlackRock Inc. lifted its stake in Marinus Pharmaceuticals by 245.4% in the 2nd quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company’s stock valued at $42,330,000 after purchasing an additional 2,769,357 shares during the last quarter. Eventide Asset Management LLC lifted its stake in Marinus Pharmaceuticals by 42.8% in the 3rd quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock valued at $36,466,000 after purchasing an additional 1,356,800 shares during the last quarter. Jennison Associates LLC lifted its stake in Marinus Pharmaceuticals by 58.4% in the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after purchasing an additional 1,089,913 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Marinus Pharmaceuticals by 415.7% in the 4th quarter. Millennium Management LLC now owns 1,082,759 shares of the biopharmaceutical company’s stock valued at $4,309,000 after purchasing an additional 872,782 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.